{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:47:17Z","timestamp":1781560037048,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.clinthera.2009.12.013","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T04:59:17Z","timestamp":1264481957000},"page":"2919-2930","source":"Crossref","is-referenced-by-count":14,"title":["Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: The Korean Individual-Microsimulation Model for Cardiovascular Health Interventions"],"prefix":"10.1016","volume":"31","author":[{"given":"Hye-Young","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Kyoung","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.12.013_bib1","series-title":"The First Korean National Health and Nutrition Examination Survey (KNHNES I)","year":"1998"},{"key":"10.1016\/j.clinthera.2009.12.013_bib2","series-title":"The Third Korean National Health and Nutrition Examination Survey (KNHNES III)","year":"2005"},{"key":"10.1016\/j.clinthera.2009.12.013_bib4","year":"2006","journal-title":"National Health Insurance Statistical Yearbook [in Korean]. Seoul, Korea"},{"key":"10.1016\/j.clinthera.2009.12.013_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4070\/kcj.2006.36.8.593","article-title":"Treatment gap in the management of hypercholesterolemia in Korea: Return on Ex- penditure Achieved for LIpid TherapY (REALITY) [in Korean]","volume":"36","author":"Kim","year":"2006","journal-title":"Korean CircJ."},{"key":"10.1016\/j.clinthera.2009.12.013_bib6","first-page":"371","article-title":"Ten centers' study on the present state of the treatment for hypercholesterolemia in patients with coronary artery disease [in Korean]","volume":"69","author":"Sung","year":"2005","journal-title":"Korean J Med."},{"key":"10.1016\/j.clinthera.2009.12.013_bib7","series-title":"Critical Appraisal of Clinical Usefulness and Cost-Effectiveness of Hyperlipidemia Drugs","year":"2007"},{"key":"10.1016\/j.clinthera.2009.12.013_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2009.12.013_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9149(02)02994-6","article-title":"Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease","volume":"91","author":"Shneck","year":"2003","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2009.12.013_bib10","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/01.CIR.0000031568.40630.1C","article-title":"Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction. A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy","volume":"106","author":"Waters","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.clinthera.2009.12.013_bib11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2009.12.013_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.acvd.2008.05.003","article-title":"Costeffectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: A French adaptation of CARDS","volume":"101","author":"Lafuma","year":"2008","journal-title":"Arch Cardiovasc Dis."},{"key":"10.1016\/j.clinthera.2009.12.013_bib13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1185\/03007990802144705","article-title":"Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men","volume":"24","author":"Peura","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2009.12.013_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00019053-200725120-00005","article-title":"Atorvastatin: A pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events","volume":"25","author":"Plosker","year":"2007","journal-title":"PharmacoEconomics."},{"key":"10.1016\/j.clinthera.2009.12.013_bib15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0002-9149(98)00641-9","article-title":"Cost-effectiveness of statins","volume":"82","author":"Huse","year":"1998","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2009.12.013_bib16","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1161\/CIRCULATIONAHA.105.607499","article-title":"Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults","volume":"114","author":"Wu","year":"2006","journal-title":"Circulation."},{"key":"10.1016\/j.clinthera.2009.12.013_bib18","series-title":"HIRA Technical Report 2006\u20132008","article-title":"Construction of National Surveillance System for Cardiovascular and Cerebrovascular Diseases [in Korean]","year":"2006"},{"key":"10.1016\/j.clinthera.2009.12.013_bib19","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/hs0901.094253","article-title":"Long-term survival and causes of death after stroke","volume":"32","author":"Br\u00f8nnum-Hansen","year":"2001","journal-title":"Stroke."},{"key":"10.1016\/j.clinthera.2009.12.013_bib20","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0895-4356(01)00405-X","article-title":"Survival and cause of death after myocardial infarction: The Danish MONICA study","volume":"54","author":"Br\u00f8nnum-Gansen","year":"2001","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.clinthera.2009.12.013_bib21","series-title":"IMS Sales Audit, 2007: Raw Data of Quarterly Market Share of Hyperlipidemia Drugs in Korea, 4Q2007","year":"2007"},{"key":"10.1016\/j.clinthera.2009.12.013_bib22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.clinthera.2007.02.001","article-title":"A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin versus simvastatin","volume":"29","author":"Rogers","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2009.12.013_bib23","series-title":"KIHASA Technical Report 2008\u20132026","article-title":"Korean Utility Weights for Major Chronic Diseases","author":"Kang","year":"2008"},{"key":"10.1016\/j.clinthera.2009.12.013_bib24","series-title":"Information disclosure for drugs reimbursement criteria: Weighted average drug prices","year":"2007"},{"key":"10.1016\/j.clinthera.2009.12.013_bib26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1365-2125.2005.02355.x","article-title":"Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention","volume":"59","author":"Perreault","year":"2005","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2009.12.013_bib27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmaco- Economics."},{"key":"10.1016\/j.clinthera.2009.12.013_bib29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0828-282X(08)70695-0","article-title":"Preventing cardiovascular disease among Canadians: Is the treatment of hypertension or dyslipidemia costeffective?","volume":"24","author":"Grover","year":"2008","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.clinthera.2009.12.013_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-200826040-00005","article-title":"An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes","volume":"26","author":"Ramsey","year":"2008","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.clinthera.2009.12.013_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00019053-200725120-00005","article-title":"Atorvastatin: A pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events","volume":"25","author":"Plosker","year":"2007","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.clinthera.2009.12.013_bib32","first-page":"681","article-title":"Costeffectiveness of lipid-lowering treatment according to lipid level","volume":"21","author":"Pilote","year":"2005","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.clinthera.2009.12.013_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1524-4733.2007.00204.x","article-title":"Development, validation, and application of a microsimulation model to predict stroke and mortality in medically managed asymptomatic patients with significant carotid artery stenosis","volume":"10","author":"Smolen","year":"2007","journal-title":"Value Health."},{"key":"10.1016\/j.clinthera.2009.12.013_bib34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00019053-200624110-00002","article-title":"Recent developments in decision-analytic modeling for economic evaluation","volume":"24","author":"Weinstein","year":"2006","journal-title":"PharmacoEconomics."},{"key":"10.1016\/j.clinthera.2009.12.013_bib35","series-title":"Methods for the Economic Evaluation of Healthcare Programmes","author":"Drummond","year":"2005"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T06:13:28Z","timestamp":1558764808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809004755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0149291809004755"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.12.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}